Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?

Nature Reviews Immunology

Volumn 10, Issue 5, 2010, Pages 299-300

  Maródi, László ^a   Casanova, Jean Laurent ^b,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; TUMOR NECROSIS FACTOR;

B CELL LYMPHOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION RISK; INFLAMMATION; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NOTE; PREDICTOR VARIABLE; PRIMARY IMMUNODEFICIENCY; PRIORITY JOURNAL; SALMONELLA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BACTERIAL INFECTIONS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951537732     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2764     Document Type: Note

References (24)

1. Wallis R. S. Curr. Opin. Infect. Dis. 22, 403-409 (2009).
2. Martin-Mola, E. & Balsa, A. Rheum. Dis. Clin. N. Am. 35, 183-199 (2009).
3. Desai, S. B. & Furst, D. E. Best Pract. Res. Clin. Rheumatol. 20, 757-790 (2006).
4. Carson, K. R. et al. N. Engl. J. Med. 361, 816-824 (2009).
5. Quartier, P. et al. Clin. Infect. Dis. 36, e47-e49 (2003).
6. Aksoy, S. et al. Leuk. Lymphoma 50, 357-365 (2009).
7. Casanova, J.-L. & Abel, L. Science 317, 617-619 (2007).
8. Maródi, L. & Notarangelo, L. D. Nature Rev. Immunol. 11, 851-861 (2007).
9. Suzuki, T. et al. J. Exp. Med. 205, 2703-2710 (2008).
10. Martinez-Moczygemba, M. et al. J. Exp. Med. 205, 2711-2716 (2008).
11. Patel, S. Y. et al. J. Immunol. 175, 4769-4776 (2005).
12. Kampmann, B. et al. J. Clin. Invest. 11 5, 2480-2488 (2005).
13. Ram, R. et al. Leuk. Lymphoma 50, 1083-1095 (2009)
14. Kimby, E. Cancer Treat. Rev. 31, 456-473 (2005).
15. Kanbayashi, Y. et al. Eur. J. Haematol. 82, 26-30 (2009).
16. Kiani-Alikhan, S. et al. Br. J. Haematol. 146, 333-335 (2009).
17. Padate, B. P. & Keidan, J. Clin. Lab. Haematol. 28, 69-71 (2006).
18. Carrasco, R. et al. Paediatr. Drugs 6, 137-146 (2004).
19. Bustamante, J. et al. Curr. Opin. Immunol. 20, 39-48 (2008).
20. Zhang, S. Y. et al. Immunol. Rev. 226, 29-40 (2008).
21. Picard, C. et al. The clinical features and outcome of IRAK-4 and MyD88 deficiencies. Medicine (in the press)
22. Major, E. O. N. Engl. J. Med. 361, 1041-1043 (2009).
23. Maródi, L. & Casanova, J.-L. Lancet 373, 2179-2181 (2009).
24. Tóth, B. et al. Mol. Immunol. 46, 2140-2146 (2009).